Gustavo Adolfo Gámez de Armas

Prof. Dr. Gustavo Adolfo Gámez de Armas

Basic and Applied Microbiology (MICROBA) Research Group, School of Microbiology, University of Antioquia, 050010, Medellín Colombia
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2010 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
IJInga Jensch
Inga Jensch
GAGustavo Adolfo Gámez de Armas
Gustavo Adolfo Gámez de Armas
MRMichael Rothe
Michael Rothe
SESandra Ebert
Sandra Ebert
MFMarcus Fulde
Marcus Fulde
Sven HammerschmidtSven Hammerschmidt
Sven Hammerschmidt

1 August 2018 in International Journal of Medical Microbiology
Verified
Journal Article
Closed access
AGAlejandro Gómez-Mejia
Alejandro Gómez-Mejia
GAGustavo Adolfo Gámez de Armas
Gustavo Adolfo Gámez de Armas
Sven HammerschmidtSven Hammerschmidt
Sven Hammerschmidt

1 March 2012 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
GAGustavo Adolfo Gámez de Armas
Gustavo Adolfo Gámez de Armas
Sven HammerschmidtSven Hammerschmidt
Sven Hammerschmidt
Streptococcus pneumoniae (pneumococcus) is an asymptomatic colonizer of the upper respiratory tract in humans. However, these apparently harmless bacteria have also a high virulence potential and are known as the etiologic agent of respiratory and life-threatening invasive diseases. Dissemination of pneumococci from the nasopharynx into the lungs or bloodstream leads to community-acquired pneumonia, septicaemia and meningitis. Traditionally, pneumococcal diseases are treated with antibiotics and prevented with polysaccharide-based vaccines. However, due to the dramatic increase in antibiotic resistance and limitations of the current available vaccines, the burden of diseases remains high. Thus, combating pneumococcal transmission and infections has emphasized the need for a new generation of proteinbased vaccines. Interactions of pneumococci with soluble host proteins or cellular receptors are crucial for adherence, colonization, transmigration of host barriers and immune evasion. Therefore, surface-exposed proteins involved in these pathogenic processes and virtually expressed by all pneumococcal strains and serotypes are the prime potential targets for an immunogenic and highly protective pneumococcal-derived carrier protein of a vaccine. In this review, we will address the state of the art in deciphering, i). the conservation, distribution and pathogenic role of recently discovered pneumococcal adhesins in colonization and invasive diseases, ii). the interactions of these virulence factors with hostproteins and receptors, iii). the subversion of the host immune and cellular responses, and iv). the potential of pneumococcal adhesins as vaccine candidates.

1 March 2011 in International Journal of Medical Microbiology
Verified
Journal Article
Closed access
BKBernd Kreikemeyer
Bernd Kreikemeyer
GAGustavo Adolfo Gámez de Armas
Gustavo Adolfo Gámez de Armas
IMImmaculada Margarit
Immaculada Margarit
JGJean Christophe Giárd
Jean Christophe Giárd
Sven HammerschmidtSven Hammerschmidt
Sven Hammerschmidt
APAndreas Podbielski
Andreas Podbielski

15 June 2012 in Molecular Oral Microbiology
Verified
Journal Article
Closed access
PDF file
SVS. Voß
S. Voß
GAGustavo Adolfo Gámez de Armas
Gustavo Adolfo Gámez de Armas
Sven HammerschmidtSven Hammerschmidt
Sven Hammerschmidt

3 January 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
GAGustavo Adolfo Gámez de Armas
Gustavo Adolfo Gámez de Armas
ACAndrés Castro
Andrés Castro
AGAlejandro Gómez-Mejia
Alejandro Gómez-Mejia
MGMauricio Gallego
Mauricio Gallego
ABAlejandro Bedoya
Alejandro Bedoya
Sven HammerschmidtSven Hammerschmidt
Sven Hammerschmidt
In recent years, the idea of a highly immunogenic protein-based vaccine to combat Streptococcus pneumoniae and its severe invasive infectious diseases has gained considerable interest. However, the target proteins to be included in a vaccine formulation have to accomplish several genetic and immunological characteristics, (such as conservation, distribution, immunogenicity and protective effect), in order to ensure its suitability and effectiveness. This study aimed to get comprehensive insights into the genomic organization, population distribution and genetic conservation of all pneumococcal surface-exposed proteins, genetic regulators and other virulence factors, whose important function and role in pathogenesis has been demonstrated or hypothesized. After retrieving the complete set of DNA and protein sequences reported in the databases GenBank, KEGG, VFDB, P2CS and Uniprot for pneumococcal strains whose genomes have been fully sequenced and annotated, a comprehensive bioinformatic analysis and systematic comparison has been performed for each virulence factor, stand-alone regulator and two-component regulatory system (TCS) encoded in the pan-genome of S. pneumoniae. A total of 25 S. pneumoniae strains, representing different pneumococcal phylogenetic lineages and serotypes, were considered. A set of 92 different genes and proteins were identified, classified and studied to construct a pan-genomic variability map (variome) for S. pneumoniae. Both, pneumococcal virulence factors and regulatory genes, were well-distributed in the pneumococcal genome and exhibited a conserved feature of genome organization, where replication and transcription are co-oriented. The analysis of the population distribution for each gene and protein showed that 49 of them are part of the core genome in pneumococci, while 43 belong to the accessory-genome. Estimating the genetic variability revealed that pneumolysin, enolase and Usp45 (SP_2216 in S. p. TIGR4) are the pneumococcal virulence factors with the highest conservation, while TCS08, TCS05, and TCS02 represent the most conserved pneumococcal genetic regulators. The results identified well-distributed and highly conserved pneumococcal virulence factors as well as regulators, representing promising candidates for a new generation of serotype-independent protein-based vaccine(s) to combat pneumococcal infections.